Skip to content

Europe CIS

Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients (“APIs”) and FDF production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide FDF medicines for commercialisation by Aspen and third parties for both domestic and export markets.

Key Countries

France
Germany
Netherlands
Russian Federation
United Kingdom

KEY BRANDS

Brand Therapeutic category
Diprivan General anaesthetic
Emla Local anaesthetic
Imuran Immunomodulator
Ovestin Estrogen hormone replacement
Xylocaine Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

2 195

June 2021

2 492

June 2020

pg5-graph1

STATISTICS

Number of products launched:

1

(2020: Nil)

Number of product recalls:

2

(2020: 3)

Average staff turnover:

11%

(2020: 11%)

Number of work-related fatalities:

Nil

(2020: Nil)

Sales representatives:

149

(2020: 225)

Revenue 2021
R’million
2020 (CER)
R’million
Change
%
Total Commercial Pharmaceuticals 5 314 5 653 (6)
Regional Brands 1 774 2 170 (18)
Sterile Focus Brands 3 540 3 483 2
Total Manufacturing 8 308 6 438 29
FDF 2 248 707 >100
API Biochem 1 243 1 183 5
API Chemicals 4 817 4 548 6
Total 13 622 12 091 13

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

Scroll To Top